News

Fusion protein boosts survival
Enlarge image

BusinessSwedenGermany

Fusion protein boosts survival

04.06.2013 - Active Biotech's immunotoxin naptumomab estafenatox has doubled overall survival in renal cell cancer patients.

A combination therapy of Active Biotech's fusion protein naptumomab estafenatox (ABR-217620), plus interferon-alpha, extended overall survival in a patient subgroup of the ANYARA Phase II/III study to 63.3 compared to 31.1 months in the interferon-alpha arm. The drug is a new class of fusion protein, which links a FAB fragment of an antibody that specifically binds to the 5T4 antigen on tumour cells with the superantigen staphylococcal enterotoxin, that induces a tumour-specific T-cell immune response.

Statistically significant benefit, however, was only achieved when patients with high levels of pre-formed antibodies against superantigens or the cytokine IL-6 were excluded. In this subgroup of 131 patients, progression-free survival improved from 5.8 months in the interferon-alpha arm to 8.5 months in the naptumomab estafenatox - interferon-alpha arm. Active Biotech is now seeking a partner for Phase III development of the targeted cancer therapy"

Renal Cell Carcinoma (RCC) affects approximately 180,000 people worldwide each year. Approximately 50 % of the patients are affected by metastases. If the disease has metastasized, average survival is around 2 years. The survival rate of patients diagnosed with renal cancer is only 5-15% after five years. The market for treatment of RCC is estimated at approximately US$2.7bn per year (EvaluatePharma March 2012). Approved first-line treatments are Sutent, Avastin in combination with IFN, Torisel and Votrient. Authorised second-line treatment are Nexavar and Everolimus.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/fusion-protein-boosts-survival.html

PoliticsEUPolandItalySpainUK

16.12.2014 Two consortia combined of 144 European companies, research institutes and universities have been selected for funding by the EIT in the areas of health and raw materials. Both clusters are set to acquire €1.1bn over the next seven years.

M&ALuxembourg

11.12.2014 Luxembourg bio-analytical testing company Eurofins Scientific has signed an agreement to acquire Boston Heart Diagnostics Corp. for an initial €112m.

StudySwitzerlandEU

10.12.2014 When it comes to the biggest investors in Research and Development (R&D) Swiss pharma top dogs Novartis and Roche have defended their positioning among the top ten companies worldwide – according to a recently published EU study.

FinancingUKSpain

09.12.2014 British drug delivery specialist Midatech Pharma plc floated on the London stock market. It is the third biotech IPO on the AIM market this year.

CooperationAustria

05.12.2014 Austrian contract research company VTU has entered into a development and commercialisation agreement with US company RCT. The partners want to combine both companies' Pichia pastoris protein production technologies under VTU's roof.

FinancingDenmark

03.12.2014 Danish biotech pharma Ascendis has successfully completed a €48m Series D financing round. The funding is expected to support its late-stage clinical trials to push its lead drug into Phase III trials.

RegulationUKFranceGermanySpain

01.12.2014 In spite of innovative new medicines on the market, the UK and Germany lag behind other countries and continue to use older medicines - especially in the treatment of cancer. French and Spanish patients, on the other hand, benefit much earlier from medical innovation.

RegulationItalyGermanyNetherlandsEU

28.11.2014 The first gene therapy for a rare genetic condition — UniQure's Glybera — is on its way to the European market. But there is a hefty price tag: Chiesi, responsible for the marketing of the orphan drug, is asking for a record price of €1.1m per patient.

Events

All Events

Current issue

All issues

Product of the week

Products